Cherry Au

Cherry Au

Auto-generated profile, based on publicly available information

Cherry Au

Rush University Medical Center, Chicago, IL

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2024 in JCO Precision Oncology
Verified
Journal Article
Open access
Arnab BasuArnab Basu
Arnab Basu
CACherry Au
Cherry Au
AKAjitha Kommalapati
Ajitha Kommalapati
HKHyndavi Kandala
Hyndavi Kandala
SSSumedha Sudhaman
Sumedha Sudhaman
ATAlan Tan
Alan Tan
PURPOSE: Tumor-informed circulating tumor DNA (ctDNA) has shown promise as a biomarker for treatment response monitoring (TRM) in a variety of tumor types, with the potential to improve clinical outcomes. We evaluated ctDNA status and dynamics during surveillance and as part of TRM with clinical outcomes in both patients with clear cell renal cell carcinoma (ccRCC) and non–clear cell renal cell carcinoma (nccRCC) treated with standard-of-care immunotherapy or targeted therapy regimens. METHODS: This was a multicenter retrospective analysis of real-world data obtained from commercial ctDNA testing (Signatera, Natera, Inc) in patients with metastatic RCC. Clinical data were collected on International Metastatic RCC Database Consortium (IMDC) risk category, pathologic subtype, and grade. RESULTS: The cohort comprised 92 patients (490 plasma samples) including both clear cell and non–clear cell histological subtypes (ccRCC: 79.3%; nccRCC: 14.1%; unclassified: 6.5%). Most of the patients belonged to the IMDC intermediate-risk category (75%, 69/92). Median follow-up was 10 months (range, 4.2-25.8). ctDNA dynamics were assessed in 56 patients on treatment, and ctDNA status was analyzed in the surveillance cohort (n = 32 patients). Serial ctDNA negativity or clearance correlated with improved progression-free survival (PFS) compared with those who became or were persistently ctDNA positive on therapy (hazard ratio [HR], 3.2; P = .012). In the surveillance cohort, patients with positive ctDNA longitudinally experienced significantly inferior PFS (HR, 18; P = .00026) compared with those who were serially negative. CONCLUSION: Collectively, we show that serial ctDNA monitoring provides prognostic information for patients undergoing treatment or surveillance, and our findings demonstrate high concordance between ctDNA status/dynamics and subsequent clinical outcomes.

1 December 2025 in JCO Precision Oncology
Verified
Journal Article
Closed access
RHRebecca Hassoun
Rebecca Hassoun
RBReuben Ben-David
Reuben Ben-David
JSJohn P. Sfakianos
John P. Sfakianos
GLGeorge Laliotis
George Laliotis
CACherry Au
Cherry Au
ACAlexander Chehrazi-Raffle
Alexander Chehrazi-Raffle
PURPOSE: Serum tumor markers (STMs), including alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG), are currently used in management of patients with germ cell tumors (GCTs). STMs in a substantial proportion of patients are normal or falsely elevated. We evaluated circulating tumor DNA (ctDNA) as a prognostic biomarker in patients with GCTs. PATIENTS AND METHODS: Longitudinal ctDNA testing was performed on a multi-institutional cohort of patients with GCTs using a clinically validated, personalized, tumor-informed 16-plex multiplex PCR-NGS ctDNA assay (Signatera, Natera Inc). ctDNA was evaluated preorchiectomy and during the molecular residual disease (MRD; 1-12 weeks postorchiectomy) and surveillance windows (>12 weeks postorchiectomy, after retroperitoneal lymph node dissection [RPLND], or postchemotherapy). The correlation between ctDNA status and event-free survival (EFS) was assessed. RESULTS: ctDNA testing was performed for 74 patients (324 plasma samples) with clinical stages I to III GCTs. The median age was 34 years (IQR, 27-39), and the median follow-up was 17 months (IQR, 12-25). Disease management postorchiectomy included surveillance in 23% (17/74), RPLND in 7% (5/74), chemotherapy in 41% (30/74), and chemotherapy + RPLND in 29% (22/74) of patients. Preorchiectomy ctDNA was detectable in 14 of 15 patients. During the MRD (N = 42) and surveillance (N = 51) windows, patients who were ctDNA-positive versus ctDNA-negative showed a significantly inferior EFS during MRD (hazard ratio [HR], 5.11 [95% CI, 1.31 to 19.95]; P = .019) and surveillance windows (HR, 12.45 [95% CI, 4.32 to 35.85]; P < .0001). By contrast, elevated versus normal STM was not associated significantly with worse EFS (MRD: HR, 2.97 [95% CI, 0.68 to 13.05]; P = .149. surveillance: HR, 1.74 [95% CI, 0.75 to 4.02]; P = .194). CONCLUSION: Tumor-informed ctDNA analysis shows promise for MRD detection in patients with GCTs. With further study, ctDNA monitoring may be useful in clinical decision making. Larger prospective trials are planned to establish clinical utility.

15 July 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MKMatthew R. Kroll
Matthew R. Kroll
CACherry Au
Cherry Au
JSJessica Slostad
Jessica Slostad
TCTrevor N. Christ
Trevor N. Christ
SPSam G. Papas
Sam G. Papas
ATAlan Tan
Alan Tan
Nephroblastoma or Wilms’ tumor (WT) is the most common pediatric renal malignancy but rare in adults. Treatment protocols for adults are typically extrapolated from pediatric guidelines, but there are no standard guidelines for adults due to the rarity of the disease. However, next-generation sequencing has led to new therapeutic options for adult WT patients. We present the first case to our knowledge of a recurrent adult WT treated with dual BRAF/MEK–targeted therapy, which showed initial robust clinical response and was well tolerated.

25 June 2025 in Oncology and Translational Medicine
Verified
Journal Article
Open access
CACherry Au
Cherry Au
CTChangtai Tian
Changtai Tian
RKRevathi Kollipara
Revathi Kollipara
DVDavid Vanderweele
David Vanderweele
TCTrevor Christ
Trevor Christ
ATAlan Tan
Alan Tan
Emerging biomarkers, such as tumor mutational burden and circulating tumor DNA (ctDNA), offer promising tools for identifying patients with prostate cancer who may benefit from immune checkpoint inhibitor therapy. This report describes an exceptional response to pembrolizumab in a patient with a microsatellite stability metastatic castration-resistant prostate cancer and ultrahigh tumor mutational burden. Additionally, this case further emphasizes the utility of ctDNA for monitoring molecular residual disease in patients whose disease burden is not adequately reflected by prostate-specific antigen levels and supports the use of ctDNA as a biomarker for personalized treatment monitoring and guiding treatment de-escalation.

22 August 2024 in Patient Education and Counseling
Verified
Journal Article
Closed access
CACherry Au
Cherry Au
ASAnnika Samuelson
Annika Samuelson
JPJaileene Perez-Morales
Jaileene Perez-Morales
MSMatthew B. Schabath
Matthew B. Schabath
EMEdith P. Mitchell
Edith P. Mitchell

30 November 2022 in Journal of General Internal Medicine
Verified
Journal Article
Open access
PDF file
CACherry Au
Cherry Au